Abstract Background
The objectives of this study were to determine quality of life (QoL) issues that are relevant to thyroid cancer patients cross-culturally and to identify those with highest relevance to them in addition to the more general issues covered by the core QoL questionnaire EORTC QLQ-C30.
Methods
A systematic literature search provided a list of potentially relevant QoL issues to supplement the core questionnaire EORTC QLQ-C30 which is widely used in research and in care and that addresses QoL issues relevant to all groups of cancer patients. A panel of experts revised this list, and thyroid cancer patients rated the issues regarding their relevance for QoL by selecting the 25 issues they would include in a thyroid cancer specific QoL module.
Results
The literature search and expert discussion provided a list of 71 QoL issues which was rated by thyroid cancer patients (n=110) from seven countries. All issues were of high priority to at least some of the patients. The most frequently selected issues were sudden attacks of tiredness, exhaustion, quality of sleep, employment, social support, fear of cancer progression, fear of second operation, difficulties swallowing, and globus sensation.
Conclusions
Thyroid cancer patients cross-culturally rate fatigue related issues as highly important for their QoL, calling for increased efforts to find successful treatments for this problem.
Vocational rehabilitation is also highly relevant for them and should therefore be an important aim of multi-disciplinary care. The third important area of concern is psychological issues, especially fear of progression and of additional treatments. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Introduction
Clinicians aim to achieve the best outcomes for their patients. But what is that -the "best outcome"? Of course, most people consider death as an outcome to be avoided and longevity as something to strive for. When it comes to quality of life (QoL), however, things become more complicated as individual values come into play [1] . For example, a 30 year old teacher who is passionate about her work and who is diagnosed with thyroid cancer perhaps finds it most important to keep a good voice so that she can pursue her work. For another person with the same diagnosis but with different priorities in life, say a 68 year old pensioner, the quality of the voice may be less important. Such differences in opinion exist not only between patients but also between an individual patient and his physician, between a doctor and her hospital manager, or between a hospital manager and the insurance company.
Value-based medicine sets out to address such disagreements [2] . It is a method of integrating the different values by one common metric, namely money spent per quality adjusted life year gained [2, 3] . In the United States, health care is already paid according to this value-based system [4] . The aim of this new system is to enable societies to apply new (often costly) medical treatments despite limited financial resources. Consequently, more and more clinical trials include value-based criteria when defining their outcomes of interest. To this end, researchers need to know what quality of life issues are most important for the majority of patients with a certain disease. However, value-based medicine should not only be understood as a method to ensure cost-effectiveness of a medical treatment but as an approach trying to address the complexity of different values in clinical decision making. The importance of this has been underlined by the U.S. Food and Drug Administration in their guidance for industry to use patient-reported outcomes for medical product development [5] .
In the treatment of patients with thyroid cancer, QoL plays a major role as their prognosis is usually very good [6, 7] . In addition, thyroid cancer tends to affect patients of a younger age This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. compared to other malignancies [8, 9] . There is evidence that young age at diagnosis may be a risk factor for decreased QoL [10] .
Whilst some studies reported that individuals with thyroid cancer generally have a QoL that is comparable to those in the general population [11, 12] , most have found an impaired quality of life [13] [14] [15] [16] [17] [18] [19] [20] [21] , comparable to patients from other tumor sites [21, 22] .
The management of thyroid cancer is multi-disciplinary -requiring active consultation and intervention using surgery, nuclear medicine, and medical treatment. This can have profound effects on the patients' physical, social and psychological well-being. Some of the QoL issues specific to thyroid cancer are related to temporary hormone-withdrawal resulting in severe fatigue, neurological deficiencies and problems associated with appetite, memory, depression, motor skills and the bowel. Damage to laryngeal nerves during thyroid surgery can result in voice issues as well. With the use of recombinant human thyroid-stimulating hormone (rhTSH) for ablation of post-surgical thyroid remnants after low-dose radioactive iodine therapy, compared with conventional thyroid hormone withdrawal, fewer symptoms occur and patients feel more vital and energetic at the time of application [23, 24] . However, QoL deficits remain a problem, not only during treatment but also in the long-term [19, 25, 26] .
For the planning of clinical trials, it is important to know what QoL issues are of highest priority to the patients. In the Netherlands, Husson et al. identified the following issues as most important to thyroid cancer survivors (n=18): stressfulness of diagnosis (82%), attention problems, decreased concentration, sudden attacks of fatigue (each 76%), problems with memory, problems with thinking, and stressfulness of radioactive iodine treatment (each 71%) [27] . From a multi-national perspective, we now aimed to identify the prioritised quality of life issues in patients from different cultural and societal backgrounds in addition to the more general issues covered by the EORTC QoL core questionnaire EORTC QLQ-C30. The This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
objective of this study was to determine the thyroid cancer specific QoL issues that are most relevant to thyroid cancer patients cross-culturally.
Methods

Identification of issues
To prepare a provisional list of QoL issues to be evaluated by patients, a systematic review was performed. It identified QoL questionnaires that are already in use with thyroid cancer patients and studies investigating QoL in thyroid cancer patients. For this review, we could build on previous work [28] . We updated this search to make sure that it was comprehensive, All issues mentioned in the studies were listed, duplicates were removed and issues with similar content were grouped. All issues that are covered by the EORTC QLQ-C30 (e.g., nausea, vomiting) or that are not quality of life issues (e.g., high blood pressure) were excluded. This list was discussed within the thyroid module developing group of the EORTC QoL Group and the group of experts decided to keep, remove or change the issues. The following professions were represented in the group of experts: nuclear medicine, radiation oncology, medical oncology, laryngo-rhino-otology, general surgery, psychology, epidemiology, rehabilitation, dentist, nurse, and nutritionist. The final list of issues was translated following the guidelines of the EORTC Quality of Life Group [29, 30] .
Data collection
The consolidated list of QoL issues was completed by thyroid cancer patients together with the QLQ-C30. In a debriefing semi-structured interview with pre-defined questions, we asked them to pick the 25 most important issues they would like to have included in a questionnaire, and to indicate relevant issues missing from this list. Missing issues mentioned by the patients were written down using the patients' wording.
Socio-demographic (age, sex, education) and clinical characteristics (histology, TNM stage, time since diagnosis, treatment) were documented on case report forms by the interviewer. All clinical data were obtained from the patients' medical charts.
Sampling
Male and female patients, aged 18 years or older and with all types and stages of thyroid cancer (International Classification of Diseases, version 10, code C73) were eligible for this study. Given the epidemiology of thyroid cancer types, we intended to include more patients with follicular and papillary cancer than patients with medullary and anaplastic types. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. However, we also wanted to make sure that the rarer disease types were represented as well.
The target sample size was therefore: at least n=25 for patients with follicular cancer, n=25 for patients with papillary, n=15 for medullary, and n=15 for patients with anaplastic cancer to ensure that sufficient patients were in each group to represent their priorities reliably, in accordance with the EORTC module development guidelines [30] . Consecutive patients attending the collaborating institutions were screened for eligibility and asked to participate.
The enrolment was monitored monthly by the principal investigator and fed back to the collaborators to ensure that the sampling complied with the pre-defined sampling matrix. We interviewed patients before, during, or after thyroid cancer treatment. Exclusion criteria were insufficient command of the local language and no written informed consent.
Statistical analysis
Data entry, cleaning, and analysis were conducted at Mainz University using STATA During patient enrolment, regular analyses regarding the frequency of patients' treatment types, cancer histology, and geographical area were performed and fed back to the multinational team of collaborators every month.
For the final analysis, the frequencies of issue priorities were calculated. Finally, a ranking of the issues was performed, starting from highest priority to lowest. This was done for the entire patient sample and for pre-defined subgroups (differentiated vs. medullary vs. anaplastic thyroid cancer; <50 vs. ≥50 years old; geographical area).
Ethics, data protection, and study registration 
Results
Issues identified from the literature
In addition to the review performed by Husson et al., we identified 118 potentially relevant studies of which 109 were excluded according to the selection criteria based on abstract screening and 9 full articles were read. Two of them fulfilled the inclusion criteria, and one additional study was found in the reference lists which had not been included in previous searches, resulting in 3 new studies [15, [31] [32] [33] . The consolidated list of issues resulting from both reviews, with duplicates and non-eligible issues removed, containing 112 items was discussed with all collaborators at a personal meeting. As a result, 44 issues were removed, 38 issues were kept, 1 new issue created, and 30 issues were re-worded. Main reasons for removal were that the issue was already covered by the EORTC QLQ-C30 with one exception: because fatigue was such an important issue in all the papers reviewed, the group decided to include additional (and more specific) issues to complement those in the EORTC QLQ-C30. Other reasons for removal were that issues were too similar and it was discussed which of the issues in question would be most suitable for the patients. The results of this This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. discussion together with explanations as for why an issue was removed or changed are displayed in Supplementary Table 1 .
Translations
While preparing the list of issues for translation, it became clear that some of the issues are difficult to translate or unclear regarding what they actually cover. For example, the question arose whether there is a difference between "being judged" (issue 6) and "social stigmatization" (issue 5). This was discussed with the EORTC Translation Unit and a revised list emerged containing 71 issues (Supplementary Table 2 ). This list was translated from English into Dutch, French, German, Greek, Hungarian, Italian, Japanese, Polish, and
Portuguese following a standardised forward-backward procedure with the help of several collaborators and the EORTC Translation Unit. For Austria and Germany, we performed two independent translations into German and resolved differences by discussion. Women represent 65.5% of the sample which is equivalent to the true distribution in thyroid cancer patients which occurs more often in women. Half of the patients had papillary disease (n=55), followed by follicular (n=30), medullary (n=17), anaplastic (n=4), and other cancer (n=4) ( Table 1 ). Other histologies were Hürthle cell carcinoma (n=2), follicular oncocytic (n=1), and follicular differentiated papillary cancer (n=1).
The mean Karnofsky performance score was 91 (SD 11, range 30-100). Time since first diagnosis varied from 1 day to 37 years with a median of 4.7 years (mean 6 years). This distribution of time since diagnosis was similar across the majority of histology types, i.e. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. papillary, follicular and medullary thyroid cancer, but distinctly shorter in patients with anaplastic cancer (mean 0.7 years, min 7 days, max 2 years).
Patients had received different types of treatment, depending on the histology and stage of their disease. The majority (85%) underwent total thyroidectomy (Table 2 ).
Many patients had received radio-active iodine (RAI) in the past, and the most frequent current treatment was tyrosine kinase inhibitors (TKI). Systemic therapy or chemotherapy is usually only considered in patients with M1 disease and in patients with non-differentiated thyroid tumors, therefore only 5 patients in our sample had received this in the past. About half of the patients (48%) were under hormone suppression at the time of the interview, and 19% received rhTSH.
Priority of issues
Of the 71 issues presented to the patients, 53 were chosen by at least 20% of the patients as high priority, i.e., they chose this issue as one of the 25 issues that should be part of a QoL questionnaire. Thirteen issues were chosen by at least 40% of the patients (see Figure 1 for the 25 top ranking issues). All issues were selected by at least 9 of the 110 patients (8%), thus each issue was of high priority to at least some patients.
Quality of life issues most frequently selected were (in descending order): being afraid of recurrence of disease, social support from family and friends, quality of sleep, sudden attacks of tiredness, social support from health care providers, physical exhaustion, employment, being afraid of second operation, globus sensation, and mental exhaustion. Table 3 displays the top 15 ranking issues in pre-specified groups according to histology (patients with differentiated vs. medullary vs. anaplastic cancer), age (below 50 years vs. 50 years and more), and geographical area (Asia vs. Europe). In all groups, social support by This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. health care providers and by family and friends was highly ranked. In all groups except in patients with anaplastic cancer, being afraid of disease recurrence, employment and sudden attacks of tiredness were highly ranked. Physical exhaustion was selected by all groups but the medullary cancer patients.
Top priorities in different subgroups
Issues highly ranked in five of the seven groups were mental exhaustion and quality of sleep.
Four of the groups prioritized: being afraid of a second operation, being a burden to others, difficulties swallowing, discomfort in the neck, globus sensation, and voice changes.
Issues that were highly ranked only in one of the groups were: fertility and problems with weight gain in younger patients only; dry mouth and joint pain in older patients; muscle pain, movement of arm or shoulder, problems with hair loss, and worries about lifelong medication only in Asian patients; chewing, facial swelling, pain in the throat, being slow, and swelling in the cheeks only in patients with anaplastic cancer.
Discussion
The aim of this study was to determine quality of life issues that are relevant to thyroid cancer patients cross-culturally and to identify the QoL issues with highest relevance to thyroid cancer patients. From the literature, we identified 71 QoL issues of potential relevance to patients in addition to the core issues covered by the EORTC QLQ-C30, and all of them were selected as highly relevant by at least some of the patients.
In all groups of patients, fatigue was a commonly prioritized QoL issue. Though fatigue is an This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Interestingly, our study participants frequently mentioned "sudden attacks of tiredness" as an important issue, along with "quality of sleep". Both issues are not often recognized as relevant in QoL questionnaires for cancer patients. The specificity of these symptoms shows how different the universe of these patients is compared to other cancer patients. It may place them in a disadvantaged position as the clinics seem at times alienated from and insensitive to this reality.
Another frequently selected issue was employment. As thyroid cancer often affects patients at a relatively young age, the disease and its treatment may have an impact on their ability to work [42] , hence successful vocational rehabilitation is an important aim of care. A study from the U.S.A. revealed that thyroid cancer patients are at higher risk of bankruptcy than other cancer patients whose disease is more aggressive [43] . In Israel, the income of thyroid cancer patients two and four years after diagnosis has recently been shown to be lower than in the general population, presumably because of part-time jobs and/or reduced physical functioning [44] . Interestingly, in our study, not only young patients had selected this issue as highly relevant but also participants older than 50 years. This may imply that patients do not like the idea of early retirement; instead they strive to stay in the workforce as long as possible.
The third area of concern for most patient groups was fear of progression. Again, this is a factor that is known to be relevant for cancer patients in general [45, 46] , but it is striking to see that this issue was on the first rank in four of the seven groups under study. Similarly, support from health care professionals and from relatives and friends was mentioned by all patient groups as one of the top priorities for QoL questionnaires. Interestingly, three quarter of the patients with anaplastic and medullary cancer selected support from health care This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. providers as highly important compared to half of the patients with differentiated thyroid tumors, probably also reflecting a higher need for support in this group. Both issues, fear of recurrence and social support, are not specific to thyroid cancer patients, but to cancer patients and survivors in general [47, 48] . It should be noted though that the thyroid cancer patients prioritized it highly. It is possible that they find it especially important, probably even more than other cancer patients, as they often experience devaluation of their anxieties by health care professionals who sometimes consider thyroid cancer to be the "good cancer" because of its ususally good prognosis [19] . However, for a patient, cancer is cancer, and this feels threatening [25, 49] .
The results of this study should be seen in the light of its limitations. The differences found between the patient groups are interesting but should be interpreted with caution. As we compared rankings, we could not adjust for relevant covariates when comparing groups. For example, 86% of the patients in Japan selected "unanswered questions about disease or treatment" as an important issue. This could imply that Japanese patients receive less information about the disease and its treatment than European patients. Another explanation would be that they find it more important to get all their questions answered compared to Europeans. The Japanese experts in our group reported that, in their experience, Japanese patients want to know everything, but when they are in front of their doctors, they hesitate to ask their doctors about their disease because they do not want to bother them about their disease or questions, even when the doctors encourages them to ask questions. This clinical observation is supported by a number of studies [50] [51] [52] [53] . However, the group of Japanese patients might also differ from the European patients in terms of other socio-demographic or disease characteristics, creating a "false" correlation between cultural area and issue priority, attributable purely to confounding. For example, the Japanese patients reported more concerns about life-long medication which could be explained by the fact that most of them were treated with TKIs. As we were not able to control for these factors statistically, as explained above, we suggest focusing on the shared QoL priorities, not on the differences between groups.
Another limitation is that we could not include many patients with anaplastic thyroid cancer due to its low incidence and poor prognosis. After discussion within our expert group we decided to calculate separate priority rankings also for this group of patients instead of combining medullary and anaplastic cancer patients to one group of non-differentiated thyroid cancer. Given the different prognosis and treatment of those patients this combination would have been arbitrary. It seemed preferable to have separate rankings, however as the number of patients with anaplastic cancer was low, they may be not representative for the entire group of patients with this histology.
Keeping these limitations in mind, we think our data provide insight into the values of thyroid cancer patients regarding their quality of life. The rankings can be used for developing a thyroid cancer specific questionnaire to assess quality of life, for clinical trials and for daily practice when trying to base decisions on patient priorities [54] . The interest of our work was to objectify issues related to the QoL of patients with thyroid cancer that in clinical practice we sometimes devalue and even deny [25] . The British Thyroid Association has acknowledged this problem and focuses now more on patient needs and QoL in their new guidelines [55] in order to improve patient care. In order to do so, site-specific questionnaires are needed to sensitively detect clinically relevant differences in QoL between groups or treatment arms. Generic tools are often not able to do so as they do not cover all relevant aspects of QoL in this group of patients [56, 57] . The results of our study can be the basis for developing such questionnaires. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
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